: Cerebral metabolism in STOP KO mice by Hanaya, Ryosuke et al.





The deletion of the STOP gene, a microtubule stabilizing factor, leads only to 
discrete cerebral metabolic changes in mice  
 
Ryosuke Hanaya, MD, PhD*, Estelle Koning*, Arielle Ferrandon*, Annie Schweitzer!, 
Annie Andrieux, PhD!, Astrid Nehlig, PhD* 
 
*INSERM U 666, 67085 Strasbourg, France and !INSERM U 366, CEA-Grenoble, 
38054 Grenoble, France 
 
Address for correspondence: Astrid Nehlig, INSERM U 666, Faculty of Medicine, 
11 rue Humann, 67085 Strasbourg Cedex, France 
Tel: (33) 390.24.32.43, Fax: (33) 390.24.32.56 
E-mail: nehlig@neurochem.u-strasbg.fr 
 
Number of pages: 20 
Number of words in abstract: 199 
Number of tables: 1 
Number of figures: 2 (including one colour figure) 
 
Running title: Cerebral metabolism in STOP KO mice 
 
Hanaya et al – 2 – 
Abstract 
 
 In mice, the deletion of the STOP protein leads to subtle anatomic changes but induces 
depleted synaptic vesicle pools, impaired synaptic plasticity, hyperdopaminergy and major 
behavioral disorders that are alleviated by neuroleptics, hence leading to a “schizophrenic-
like” phenotype. In this study, we applied the quantitative autoradiographic [14C]2-
deoxyglucose technique to study to which extent basal rates of cerebral glucose utilization in 
STOP KO mice occur in the regions where metabolic changes have been reported in 
schizophrenic patients. Studies were performed on wild type, heterozygous and homozygous 
STOP KO mice (7-8 per group). Mice were implanted with femoral artery and vein catheters 
and cerebral glucose utilization was quantified over 45 min. Compared to wild type mice, 
glucose utilization in STOP KO mice was significantly increased in olfactory cortex, 
ventromedian and anterolateral hypothalamus, ventral tegmental area and substantia nigra 
pars compacta. Non significant increases, ranging between 9 and 19%, were recorded in the 
whole auditory system, CA1 pyramidal cell layer and dorsal raphe. Glucose utilization was 
also significantly increased in heterozygous compared to wild type mice in olfactory cortex. 
These data might reflect hyperdopaminergic activity, olfactory deficits and disturbances in 
sleep in STOP KO mice that are also reported in schizophrenic patients.  
 
Key words: cerebral glucose metabolism, cytoskeleton, microtubules, STOP protein, 
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Introduction 
 
 Microtubules play a pivotal role in many vital cell functions, including cell divison, 
morphogenesis and vesicle trafficking (Dustin, 1984). They are particularly abundant in 
neurons and tubulin itself accounts for 20% of neuronal proteins. Neuronal microtubules are 
mandatory for dendritic and axonal trafficking, and the disturbance of these transports by 
drugs aimed at microtubules as the members of the taxol family used in cancer therapy 
induces neuropathies (Pazdur et al., 1993). Microtubules act as dynamic polymers, exhibiting 
both large spontaneous length fluctuations and treadmill-type behavior (Margolis and Wilson, 
1978; Mitchison and Kirschner, 1984). Many cell types, including neurons and glial cells 
contain microtubule-stabilizing factors that can block microtubule dynamics and prevent 
microtubules assemblies from depolymerizing, as for example in the cold (Baas et al., 1994; 
Bosc et al., 2003). The microtubule-associated proteins STOPs are responsible for the high 
degree of stabilization displayed by neuronal and non-neuronal microtubules (Bosc et al., 
1996; Denarier et al., 1998; Galiano et al., 2004). More recently it has been shown that 
STOP is phosphorylated by the multifunctional enzyme calcium/calmodulin-dependent 
protein kinase II (CaMKII). Phosphorylated forms of STOP do not bind microtubules but co-
localize with actin assemblies and with clusters of synaptic proteins, in differentiated neurons 
and could be important for STOP function in synaptic plasticity (Baratier et al., 2006). 
Furthermore, STOP proteins have the capacity to associate with Golgi material (Gory-Faure 
et al., 2006) and in light of studies indicating that the presence of Golgi material in neurites 
and synapses may be important for synaptic plasticity (Horton and Ehlers, 2004), a Golgi 
interaction with STOP could be important for STOP function in synapses. 
 The STOP protein was recently deleted in mice. The neuronal deficits induced by the 
STOP protein deletion do not induce overt anatomical alterations but affect short- and long-
term synaptic plasticity in the hippocampus where depleted glutamatergic synaptic vesicle 
pools were found (Andrieux et al., 2002). The cerebral reduction of glutamate release to the 
synaptic cleft leads to reduced stimulation of postsynaptic glutamate receptors and increased 
glutamine metabolism in the vicinity of the postsynapse (Brenner et al., 2007). Correlatively, 
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synaptophysin, VGlut1, GAP-43 and spinophilin mRNAs are decreased in the hippocampus 
in STOP null mice (Eastwood et al., 2007). STOP KO mice display also a multiplicity of 
behavioral disorders, mainly disorganized activity with frequent shifts between 
hyperlocomotion and prostration, dramatic perturbations of maternal behavior including 
nurturing defects, anxiety-like behavior, severe social withdrawal, perturbed interactions with 
the physical environment and decreased time spent in feeding and sleeping (Andrieux et al., 
2002). They also exhibit alterations in tests usually used to measure “schizophrenic-like 
behavior”, mainly in sensory-motor gating mechanisms and locomotor hypersensitivity to 
stress (Fradley et al., 2005). These mice also exhibit increased dopaminergic 
neurotransmission and increased efflux of dopamine in the nucleus accumbens upon 
stimulation (Brun et al., 2005). Most behavioral and dopaminergic disturbances are alleviated 
by neuroleptic treatment (Andrieux et al., 2002; Brun et al., 2005; Fradley et al., 2005) and by 
the treatment with a microtubule stabilizing agent, epothilone D (Andrieux et al., 2006) that is 
a taxol-related compound that interacts with tubulin to stabilize microtubules (Kolman, 2004; 
Wang et al., 2005).  
 In the STOP KO mouse, the neurotransmission disturbances are mainly characterized by 
hypo-glutamatergy associated with hyper-dopaminergy, currently considered to be a 
landmark of schizophrenia (Frankle et al., 2003). In order to confirm whether or not these 
neurochemical defects may correlate with functional deficits reminiscent of schizophrenia, as 
reported in the human literature (for review see Wong and Van Tol, 2003), in the present 
study, we measured the basal cerebral metabolic rates for glucose (LCMRglcs) in STOP KO 
mice compared to wild type and heterozygous littermates by means of the quantitative 
autoradiographic [14C]2-deoxyglucose (2DG) technique (Sokoloff et al., 1977) adapted to the 
mouse (Jay et al., 1985; Bouilleret et al., 2000).  
 
Materials and methods 
 
Animals and measurement of LCMRglcs 
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STOP KO male mice, heterozygous and control wild-type (WT) littermates were 
generated as previously described (Andrieux et al., 2002). Mice were housed eight per cage 
and maintained in quiet, uncrowded facilities (room temperature of 21-22°C) on 12 hour light-
dark schedule (7:00 a.m., lights on) and given unlimited access to lab chow and water. Males 
only were used for these experiments to eliminate confounding effects of variable estrogen 
level on neuronal excitability (Murphy et al., 1998) and fluctuations in metabolic rates with the 
estrus cycle (Nehlig et al., 1985). The autoradiographic experiments were performed on a 
total number of 23 mice, eight WT, seven heterozygous and eight STOP KO mice. All animal 
experimentation was performed in accordance with the rules of the European Committee 
Council Direction of November 24, 1986 (86/69/EEC) and the French Department of 
Agriculture (Licence N°67-97).  
A femoral artery and vein were catheterized with polyethylene catheters (Clay Adams PE 
10) under light halothane anesthesia. Because of the erratic and unpredictable locomotor 
behavior of STOP KO mice, the animals were placed in loose-fitting abdomino-pelvic plaster 
casts to immobilize the lower part of their body, as originally described and performed in 
numerous studies (Sokoloff et al., 1977; Nehlig et al., 1984). Both catheters were running 
outside the left hindpaw to allow easy access for injection and blood sampling. The animals 
were allowed to recover from surgery for at least 3 h before the onset of the experiment. A 
minimal duration of 2 h is usually applied to allow the animals to fully recover from 
anesthesia (Sokoloff et al., 1977; Nehlig et al., 1984, 1985; Bouilleret et al., 2000). Catheters 
were inserted between 8:30 a.m. and 11:30 a.m. The 2DG measurements were performed 
between 1:30 and 3:30 p.m. All the animals were sacrificed between 2:30 and 3:30 p.m. Not 
more than two to three mice were studied on a given day. This procedure was followed to 
keep experimental and surrounding conditions as constant as possible to avoid disturbances 
in brain metabolism unrelated to the deletion of the STOP gene. 
 LCMRglcs were measured by the [14C]2-deoxyglucose (2DG) technique (Sokoloff et al., 
1977) adapted to mice (Jay et al., 1985; Bouilleret et al., 2000). The [14C]2DG (4.625 MBq/kg, 
specific activity 1.65-2.04 GBq/mmol, NEN, France) was injected as an i.v. pulse. Timed 
arterial blood samples were drawn over the following 45 min for the measurement of plasma 
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glucose and 2DG concentrations. At approximately 45 min after the injection of the tracer, 
the animals were sacrificed by decapitation. Brains were rapidly removed, frozen and cut into 
20 µm coronal sections. According to the classical procedure described by Sokoloff et al. 
(1977), within each series of ten consecutive sections, the first four ones were taken for 
autoradiography, the fifth one was stained with thionine and the next five ones were 
discarded. Sections were autoradiographed on Amersham Biomax MR film along with 
[14C]methylmethacrylate standards calibrated for their 14C concentration in brain tissue. The 
autoradiographs were then digitized and analyzed by densitometry with an image processing 
system (Biocom 500, Les Ulis, France). The localization of specific nuclei was assessed on 
the adjacent sections stained with thionine according to the mouse brain atlas of Franklin and 
Paxinos (1997). The whole surface of the brain regions studied was delineated by hand with 
the image processing system and the optical density of each brain region was read bilaterally 
in a minimum of four consecutive brain sections for symmetrical regions and in eight sections 
for central regions. LCMRglcs were calculated according to the operational equation of the 
2DG method using the integrated specific activity of the ratio between the plasma [14C]2DG 
and glucose concentrations measured for each animal, and the usual rate constants 




LCMRglcs were determined in 64 regions of three groups of 7-8 animals, i.e., WT, 
heterozygous and STOP KO mice. A global statistical analysis was performed using an 
analysis of variance for repeated measures (within factor, structures and between factor, 
group). To locate the differences in LCMRglcs in each structure between the WT control 
group, the heterozygous and STOP KO mice groups, post-hoc analyses were performed 
using with Bonferroni’s t-test corrected for multiple comparisons. Conservative multiple 
comparisons were chosen to reduce the likelihood of type II errors in view of the large 
number of statistical comparisons performed. 
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Results 
 
 In heterozygous mice, LCMRglcs significantly increased over the levels recorded in WT 
mice in one single region, the olfactory cortex (Table 1, Figure 1). This significant increase 
over control levels was also found in STOP KO mice. In STOP KO mice, LCMRglcs were 
also significantly increased over control WT levels in two dopaminergic cell groupings, the 
ventral tegmental area and the substantia nigra pars compacta, and two hypothalamic nuclei, 
the anterolateral and ventromedial (Table 1, Figures 1, 2). In the latter nucleus, LCMRglcs 
were also significantly higher in STOP KO than in heterozygous mice.  
In addition, LCMRglcs were increased, though non significantly, by values equal to or 
larger than 10% in 14 regions of the KO STOP mice (Table 1, Figures 1, 2). Metabolic 
increases, recorded in STOP KO compared to WT mice occurred in the dorsal raphe nucleus 
(+14%), cerebellar cortex (+11%), anterior hypothalamic nucleus (+11%), CA1 pyramidal cell 
layer of the hippocampus (+11%) and median forebrain bundle (+10%). Likewise, rates of 
LCMRglc were higher in most areas of the auditory system of STOP KO compared to WT 
mice. This was the case for the auditory cortex, medial geniculate body, inferior colliculus, 
lateral lemniscus and superior olive in which metabolic rates were increased by 9-19%.  
There were no metabolic differences between WT and STOP KO mice in the limbic 




 The present data show that, in basal conditions, the levels of functional activity display a 
general tendency to increase throughout the brain which may reflect the ubiquitous 
distribution of the protein (Couégnas et al., 2007). However, metabolic rates significantly 
increased in STOP KO compared to WT mice only in a few scattered regions.  
 
The dopaminergic system 
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 The most striking differences recorded in STOP KO mice compared to WT control mice 
were significant increases in LCMRglcs in the two dopaminergic cell groupings, the ventral 
tegmental area and the substantia nigra, pars compacta and the tendency to an increase 
(+10%) in the median forebrain bundle containing the fibers running from the ventral 
tegmental area and the substantia nigra, pars compacta to the nucleus accumbens and 
striatum, respectively. Conversely, in the nucleus accumbens and striatum, LCMRglcs were 
identical in STOP-KO and wild type mice, which is in accordance with normal basal levels of 
dopamine measured by microdialysis in the extracellular space of those structures (Brun et 
al., 2005). This is also in agreement with a normal response to tonic stimulation in the 
nucleus accumbens and striatum. The tonic stimulation corresponds to the discharge of 
dopaminergic neurons in a low regular spiking mode allowing to establish a steady state level 
of dopamine efflux responsible for the basal level of the monoamine (Brun et al., 2005 and 
references therein). However, the STOP-KO mice were reported to display an enhanced 
response to phasic stimulation in the nucleus accumbens. The phasic stimulation 
corresponds to a high frequency bursting discharge eliciting transient increases of dopamine 
efflux on top of the dopamine basal tone (Brun et al., 2005 and references therein). These 
larger responses to phasic stimulation in the STOP-KO mice may be facilitated by a higher 
functional activity in the regions containing dopaminergic cells bodies, mainly the ventral 
tegmental area, as measured here already at the basal level. Likewise, models of 
schizophrenia (Grace, 1991) and positron emission tomography (PET) studies in humans 
have reported a presynaptic dopaminergic abnormality in schizophrenic patients translating 
into elevated dopamine release in response to stimulation but no increase in basal 
dopaminergic impregnation (Laruelle et al., 1996; Breier et al., 1997; Abi-Dargham et al., 
1998; Ginovart et al., 1999) which is consistent with the data of the present study.  
 
Hypothalamus and sleep 
The deletion of the STOP gene led also to metabolic increases in the anterolateral and 
ventromedial hypothalamic nuclei. STOP KO mice spend less time sleeping and exhibit 
fragmentation of sleeping times (Andrieux et al., 2002). The anterolateral hypothalamic 
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nucleus is involved in sleep regulation and the ventromedial nucleus in emotions (Szymusiak 
et al., 1998). The stimulation of ventromedial hypothalamic regions strongly excites the 
stimulatory reticular formation, hence causing wakefulness, attention and agitation. 
Conversely, the stimulation of the anterior part of the hypothalamus leads to somnolence and 
sometimes sleep (Ticho and Radulovacki, 1991) while the lesion of this region results in 
persistent insomnia (Szymusiak and Satinoff, 1984; Sallanon et al., 1989). Thus, the 
increased metabolic activity of these two nuclei may reflect the disturbed regulation of 
wakefulness and sleep and decreased sleeping time observed in STOP KO mice (Andrieux 
et al., 2002). In schizophrenic patients, some sleep disturbances were reported, expressed 
mainly as sleep-onset and maintenance insomnia, and increased latency to various phases 
of sleep (Monti and Monti, 2004). 
 
The olfactory cortex and hippocampus 
There is also a significant change in LCMRglcs in the primary olfactory cortex and this 
increase appears to be quite robust because it can be recorded to the same extent in both 
homozygous STOP KO mice and heterozygous mice which means that the lack of one copy 
of the gene is already disturbing functional activity of this region. This may be in relation with 
the particularly high density of the STOP protein in the olfactory glomeruli (Andrieux et al., 
2002; Couégnas et al., 2007) which leads to a change in function already after a partial gene 
deletion. Olfactory function has not yet been tested in heterozygous or homozygous STOP 
KO mice. In schizophrenic patients, phosphorylation-independent MAP2 expression which 
participates in the modification of synaptic organization is significantly reduced (Rioux et al., 
2004) and cell cycle alterations can be found in the olfactory epithelium (McCurdy et al., 
2006). Substantial olfactory deficits in schizophrenic patients, such as deficits in odor 
identification, discrimination, treatment of information and memory are well documented 
(Moberg et al., 1999; Hudry et al., 2002; Rupp et al., 2005). Furthermore, in humans, 
olfactory identification is impaired in relatives of patients with familial schizophrenia (Kopala 
et al., 2001) or in monozygotic twins discordant for schizophrenia (Ugur et al., 2005), which 
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may relate to the increase in metabolic activity measured here in the olfactory cortex of 
heterozygous mice.  
In the hippocampus, the deletion of the STOP gene leads to an impairment of long-term 
potentiation and long-term depression at the level of Schaffer collateral-CA1 pyramidal cell 
synapses where LCMRglcs increased by 11% over WT mice levels but this change was not 
statistically significant. Conversely, long-term potentiation and paired-pulse facilitation were 
identical in STOP KO and WT mice at mossy fiber-CA3 pyramidal cell synapses (Andrieux et 
al., 2002), where LCMRglcs were identical in STOP KO and WT mice. Thus, the tendency to 
a metabolic increase only in CA1 but not in CA3 pyramidal cells may be in relation with the 
specific change of electrophysiological properties at the level of the Schaffer collaterals-CA1 
pyramidal cells pathway (Andrieux et al., 2002) and with the specific reduction of 
synaptophysin mRNA expression in CA1 versus CA3 regions in STOP null mice (Eastwood 
et al., 2007). These regional differences in function in the hippocampus were observed 
despite a similar density of the STOP lacZ reporter gene in CA1 and CA3 pyramidal cells 
(Couégnas et al., 2007). Moreover, glutamatergic vesicle pools are depleted in the 
hippocampus (Andrieux et al., 2002) and glutamate synthesis is reduced in heterozygous 
and STOP KO mice leading to reduced stimulation of postsynaptic glutamate receptors 
(Brenner et al., 2007). These disturbances are in accordance with the hypothesis of an 
alteration of glutamatergic neurotransmission as a potential underlying cause of 
schizophrenia (Goff and Coyle, 2001; Frankle et al., 2003). 
 
The auditory system 
Functional activity was increased in the whole auditory pathway of STOP KO mice, 
starting at the level of the first posterior relays, superior olive and lateral lemniscus followed 
by inferior colliculus, midbrain medial geniculate body and the projection on the auditory 
cortex. These increases ranged from 9 to 19% in all regions but were not statistically 
significant. Schizophrenic patients have a characteristic pattern of response to test sounds 
with reduced amplitude and increased latency of the p300 wave of the auditory evoked 
potentials (Blackwood et al., 1991; Mathalon et al., 2000). This pattern is a trait marker of the 
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disease (Mathalon et al., 2000), indicating some impairment of auditory function and 
processing of sensory information (Siegel et al., 1984). In addition, schizophrenia-related 
auditory hallucinations (Andreasen and Black, 1991; Spitzer et al., 1994) seem to originate in 
abnormal coactivation in regions related to the acoustical processing of external stimuli 
(Aleman et al., 2003; Hubl et al., 2004). In STOP KO mice, the auditory function per se does 
not seem to be altered (JL Puel and A Andrieux, unpublished observations) but the auditory 
evoked potentials were not measured and need to be studied in more detail in STOP KO 
mice. Moreover, the amount of change in functional activity in a given structure necessary to 
impact on the function of this structure is not known  
 
To which extent might STOP KO mice be considered a model of schizophrenia? 
 Although number of metabolic changes recorded in STOP KO mice may reflect a 
schizophrenic phenotype, differences can also been noted. The “hypofrontality” classically 
reported in naïve and medicated schizophrenic patients, characterized by decreased 
functional activity in anterior brain regions (Weinberger et al., 1986; Geraud et al., 1987; 
Liddle et al., 1992; Min et al., 1999), was not found in STOP KO mice. Hypometabolism in 
frontal (and sometimes parietal) cortex is usually associated with negative symptoms at rest 
(Wolkin et al., 1992; Kaplan et al., 1993; Yuasa et al., 1995; Sabri et al., 1997; Lahti et al., 
2006) which were reported in STOP KO mice (Andrieux et al., 2002; Fradley et al., 2005). 
Positive symptoms correlate positively with increased functional activity in the 
hippocampal/parahippocampal region (Lahti et al., 2006) which tended to be slightly 
activated in STOP KO mice. Conversely to human reports (Clark et al., 2001), no metabolic 
change could be recorded in the thalamus of STOP KO mice studied in controlled basal 
conditions, despite the quite strong expression of the STOP lacZ reporter gene in several 
thalamic nuclei (Couégnas et al., 2007). 
 The STOP protein is a candidate to participate in the role that microtubules may play in 
the pathophysiology of schizophrenia (Kerwin, 1993). The STOP deletion-induced changes 
in the expression of synaptic protein mRNAs are reminiscent of those reported in 
schizophrenia (Eastwood et al., 2007). A recent case-control genetic study on 35 
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schizophrenic patients reported an association between the STOP gene and schizophrenia. 
In patients, the mRNAs of two isoforms of the STOP mRNA, and mainly isoform 2 were up-
regulated in the prefrontal cortex compared to control cases (Shimizu et al., 2006). Thus, 
variable regional changes in the cellular content of the STOP protein may underlie the 
expression of the disease. However, the gene KO technology, as applied here, leads to 
generalized suppression of the protein which most likely explains the discrepancies between 
the disorder and the present model. Further work in both humans and animals applying more 
subtle and regional gene deletions may be necessary to obtain a model closer to the 
pathophysiology of the disorder. 
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Legend to Figure 1 
 
Figure 1: Effects of the deletion of the STOP gene on LCMRglcs in heterozygous and 
homozygous STOP KO mice. Values represent means ± S.D. of 7-8 animals and are 
expressed as percent of the corresponding level in wild type animals. 
* p < 0.05, ** p < 0.01, statistically significant differences from levels in wild type mice 
° p < 0.05, statistically significant difference from levels in heterozygous mice. 
Abbreviations: OLFCX: olfactory cortex, ALHYP: anterolateral hypothalamus, VMHYP: 
ventromedian hypothalamus, VTA: ventral tegmental area, SNPC: substantia nigra, pars 
compacta, AUDCX: auditory cortex, MGEN: medial geniculate body, ICOL: inferior colliculus, 
LL: lateral lemniscus, SO: superior olive, CA1: hippocampal CA1 pyramidal cell layer, MFB: 
median forebrain bundle, DRAP: dorsal raphe, CBCX: cerebellar cortex. 
 
Figure 2: 2DG autoradiograms of brain sections of a wild type control (WT) and a STOP KO 
mouse taken at the level of the midbrain. Compared to the wild type mouse, brain 
metabolism is increased in the STOP KO mouse at the level of the substantia nigra pars 
compacta (SNPC), the ventral tegmental area (VTA), the auditory cortex (AUDCX), the CA1 
pyramidal cell layer of hippocampus (HIP) and the thalamus (THAL). 
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Table 1. Local cerebral metabolic rates for glucose in wild type (WT), heterozygous and 
STOP KO mice. 
 
 Wild type 
mice (n = 8) 
Heterozygous mice 









Cerebral cortex      
Olfactory  100.4 ± 4.6 117.3 ± 9.7** + 17 114.2 ± 9.1* + 14 
Prefrontal 74.8 ± 6.2 77.0 ± 6.6 + 3 80.4 ± 9.9 + 7 
Frontal 84.0 ± 13.3 84.6 ± 6.0 + 1 87.5 ± 8.8 + 4 
Anterior cingulate 98.3 ± 16.9 98.9 ± 9.4 + 1 98.0 ± 8.1 0 
Piriform 64.8 ± 8.4 62.0 ± 5.2 - 4 63.6 ± 3.0 - 2 
Parietal 85.5 ± 11.9 84.6 ± 6.2 - 1 86.6 ± 0.9 + 1 
Motor 82.8 ± 13.1 84.1 ± 5.5 + 2 87.2 ± 3.3 + 5 
Auditory 113.7 ± 7.2 116.6 ± 9.9 + 3 126.1 ± 8.9 + 11 
Entorhinal 61.1 ± 5.2 62.8 ± 5.3 + 3 60.8 ± 1.7 0  
Visual 89.1 ± 12.5 90.3 ± 11.9 + 1 85.5 ± 8.7 + 4 
Sensory systems      
Medial geniculate 119.3 ± 15.7 126.1 ± 19.4 + 6 131.9 ± 6.8 + 11 
Lateral geniculate 101.1 ± 11.6 106.2 ± 7.4 + 5 109.2 ± 10.9 + 8 
Superior colliculus 84.6 ± 8.3 87.0 ± 9.8 + 3 86.8 ± 7.4 + 3 
Inferior colliculus 158.6 ± 19.3 158.0 ± 18.7 0 172.7 ± 32.2 + 9 
Lateral lemniscus 110.9 ± 17.7 127.1 ± 13.5 + 15 124.5 ± 28.6 + 12 
Superior olive 125.4 ± 13.8 147.0 ± 19.7 + 17 149.3 ± 41.3 + 19 
Cochlear nucleus 119.0 ± 7.6 120.6 ±15.0 + 1 118.2 ± 9.9 - 1 
Vestibular nucleus 145.9 ± 15.0 145.6 ±7.7 0 155.3 ± 11.7 + 6 
Limbic system      
Medial septum 67.7 ± 6.4 71.7 ± 3.6 + 6 72.4 ± 9.7 + 7 
Lateral septum 65.0 ± 5.6 66.8 ± 3.3 + 3 72.0 ± 14.2 + 7 
Nucleus accumbens 62.9 ± 6.0 63.1 ± 1.8 0 62.4 ± 2.9 - 1 
Hippocampal CA1 48.0 ± 7.6 49.1 ± 4.0 + 2 53.4 ± 8.8 + 11 
Hippocampal CA2 49.5 ± 7.8 46.1 ± 3.0 - 7 49.1 ± 5.9 - 1 
Hippocampal CA3 65.6 ± 10.8 62.6 ± 2.0 - 5 66.4 ± 7.1 + 1 
Hippocampal CA4 51.2 ± 7.8 50.6 ± 1.7 - 1 50.2 ± 5.5 - 2 
Dentate gyrus 60.4 ± 3.9 57.8 ± 2.8 - 4 62.6 ± 2.4 + 4 
Medial amygdala 39.7 ± 5.0 40.5 ± 3.3 + 2 39.6 ± 4.4 0 
Central amygdala 37.4 ± 3.4 38.4 ± 2.3 + 3 33.4 ± 4.6 - 11 
Basolateral amygdala 71.8 ± 8.8 71.4 ± 5.6 0 74.2 ± 5.5 + 3 
Ventral tegmental area 77.1 ± 7.6 79.2 ± 4.6 + 3 84.2 ± 3.8* + 9 
Mesencephalic 
reticular formation 
66.1 ± 8.6 61.5 ± 7.9 - 7 62.1 ± 8.6 - 6 
Mammillary body 135.9 ± 16.5 154.4 ± 17.7 + 14 144.8 ± 22.7 + 7 
Pontine grey 49.1 ± 7.0 52.6 ± 4.9 + 7 52.1 ± 6.6 + 6 
Dorsal raphe 72.0 ± 8.7 72.0 ± 5.0 0 82.4 ± 6.4 + 14 
Median raphe 96.9 ± 6.4 101.0 ± 3.0 + 4 96.9 ± 1.1 0 
Locus coeruleus 72.4 ± 3.4 71.7 ± 3.4 - 1 75.9 ± 3.2 + 5 
Medullary reticular 
formation 
61.1 ± 6.5 63.5 ± 2.1 + 4 68.5 ± 4.5 + 12 
Hypothalamus      
Anterior 48.5 ± 6.7 52.0 ± 3.6 + 7 53.8 ± 3.9 + 11 
Anterolateral 45.1 ± 7.9 49.7 ± 2.0 + 10 54.8 ± 0.5** + 22 
Paraventricular 47.3 ± 6.4 48.2 ± 3.6 + 2 49.6 ± 2.0 + 5 
Median forebrain 
bundle 
60.3 ± 4.7 64.4 ± 3.0 + 6 66.6 ± 11.1 + 10 
Ventromedial 40.7 ± 5.7 42.8 ± 3.7 + 5 51.3 ± 5.7*° + 26 
Dorsomedial 48.1 ± 4.3 47.5 ± 4.4 - 1 52.0 ± 5.8 + 8 
Thalamus      
Hanaya et al – 20 – 
Anteromedial 115.2 ± 10.7 114.4 ± 13.9 - 1 113.5 ± 6.9 - 1 
Anteroventral 115.5 ± 12.7 116.0 ± 9.1 0 122.8 ± 7.2 + 6 
Ventromedial 114.1 ± 9.3 114.2 ± 11.2 0 114.6 ± 9.8 0 
Mediodorsal 112.8 ± 12.6 120.1 ± 15.4 + 6 117.3 ± 11.3 + 4 
Lateral 105.7 ± 14.4 113.2 ± 11.1 + 7 112.3 ± 10.2 + 6 
Ventroposteromedial 85.3 ± 8.5 88.7 ± 7.6 + 4 87.0 ± 10.6 + 2 
Posteromedial 78.0 ± 7.0 80.0 ± 8.4 +3 81.8 ± 8.2 + 5 
Posterior 95.6 ± 10.0 101.8 ± 11.0 + 6 102.8 ± 11.9 + 8 
Paraventricular 62.8 ± 5.3 60.3 ± 2.8 - 4 62.6 ± 9.0 0 
Motor system      
Caudate nucleus 98.9 ± 5.8 99.6 ± 3.7 + 1 98.1 ± 8.0 - 1 
Globus pallidus 55.0 ± 4.8 55.3 ± 3.8 0 54.8 ± 6.0 0 
Subthalamic nucleus 86.7 ± 10.2 92.1 ± 5.5 + 6 88.2 ± 5.0 + 2 
Substantia nigra, pars 
reticulata 
52.7 ± 7.0 51.2 ± 6.0 - 3 53.6 ± 4.9 + 2 
Substantia nigra, pars 
compacta 
79.3 ± 7.8 83.6 ± 5.6 + 5 90.2 ± 5.8**° + 14 
Red nucleus 86.9 ± 8.6 93.7 ± 7.0 + 8 94.2 ± 8.7 + 8 
Cerebellar cortex 56.7 ± 3.9 58.8 ± 3.6 + 3 62.9 ± 4.4 + 11 
Dentate nucleus 99.4 ± 6.3 103.2 ± 9.0 + 4 99.9 ± 6.9 + 1 
Fastigial nucleus 110.6 ± 8.2 115.8 ± 8.7 + 5 108.9 ± 11.0 - 2 
Interpositus nucleus 113.1 ± 8.8 112.9 ± 8.8 0 107.3 ± 5.8 - 5 
White matter      
Genu of the corpus 
callosum 
27.2 ± 2.5 29.7 ± 4.1 + 9 27.0 ± 9.8 - 1 
Cerebellar white 
matter 
35.5 ± 3.1 35.9 ± 4.8 + 1 33.8 ± 3.1 - 5 
 
Values expressed as µmol/100g/min represent means ± S.D. of the number of animals in 
parentheses. 
* p < 0.05, ** p < 0.01, statistically significant differences from wild type mice 
° p < 0.05, statistically significant differences between heterozygous and STOP KO mice 
 
Hanaya et al – 21 – 
 
 
Figure 2 
 
 
